trifluridine has been researched along with Body Weight in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Dechow, T; Ettrich, TJ; Fruehauf, S; Fuchs, M; Heinemann, V; Hoyer, I; Kaiser, F; Karthaus, M; Kiani, A; König, A; Kurreck, A; Modest, DP; Müller, L; Quante, M; Reinacher-Schick, A; Roderburg, C; Schwaner, I; Sommerhäuser, G; Stahler, A; Stintzing, S; von Weikersthal, LF | 1 |
| Nakagawa, F; Nukatsuka, M; Takechi, T | 1 |
| Emura, T; Fujioka, A; Fukushima, M; Ohshimo, H; Suzuki, N | 1 |
1 trial(s) available for trifluridine and Body Weight
| Article | Year |
|---|---|
Study protocol of the FIRE-8 (AIO-KRK/YMO-0519) trial: a prospective, randomized, open-label, multicenter phase II trial investigating the efficacy of trifluridine/tipiracil plus panitumumab versus trifluridine/tipiracil plus bevacizumab as first-line tre
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Body Weight; Clinical Trials, Phase II as Topic; Colorectal Neoplasms; Fluorouracil; Humans; Multicenter Studies as Topic; Panitumumab; Prospective Studies; Pyrrolidines; Randomized Controlled Trials as Topic; Thymine; Trifluridine | 2022 |
2 other study(ies) available for trifluridine and Body Weight
| Article | Year |
|---|---|
Efficacy of Combination Chemotherapy Using a Novel Oral Chemotherapeutic Agent, TAS-102, with Oxaliplatin on Human Colorectal and Gastric Cancer Xenografts.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Cell Death; Cell Proliferation; Colorectal Neoplasms; Drug Combinations; HCT116 Cells; Humans; Mice, Nude; Organoplatinum Compounds; Oxaliplatin; Pyrrolidines; Stomach Neoplasms; Thymine; Treatment Outcome; Trifluridine; Tumor Burden; Uracil; Xenograft Model Antitumor Assays | 2015 |
Potentiation of the antitumor activity of alpha, alpha, alpha-trifluorothymidine by the co-administration of an inhibitor of thymidine phosphorylase at a suitable molar ratio in vivo.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Cell Line, Tumor; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Synergism; Enzyme Inhibitors; Humans; Macaca fascicularis; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neovascularization, Pathologic; Thymidine; Thymidine Phosphorylase; Time Factors; Trifluridine; Xenograft Model Antitumor Assays | 2005 |